Deal-Hungry Sanofi Shouldn't Overpay for Actelion

Pharma giant Sanofi risks paying too much for a rare-disease biotech.

from WSJ.com: Markets http://ift.tt/2hu8Oix
via https://ifttt.com/ IFTTT